Israel Active

The International Fellowship of Christians and Jews has funded a 100-patient Emergency Operations Center in a fortified sheltered area of Emek Medical Center in the Galilee. The IFCJ is also funding a 50-patient fortified space in the hospital’s oncology building.

Some 200 Israeli medical students were studying overseas but returned to join the IDF. Israel’s Ministry of Health has requested the deans of Israeli medicine faculties to help to integrate these students in Israeli hospitals and medical schools at the end of the war.

An additional NIS 650 million will be added to Israel's health basket as part of the war efforts.

Stanford Institute for Stem Cell Biology and Regenerative Medicine is to using the AML(acute myeloid leukemia) detection kits from Israel’s Sequentify (see previously) in its leukemia research. Sequentify's Infiniseq technology cuts DNA sequencing time to only 3.5 hours.

Israel’s Medial EarlySign (see previously) has partnered US-based Geisinger to identify patients at high risk for respiratory or pulmonary diseases such as lung cancer. Their LungFlag AlgoMarker analyzes data from a patient’s electronic health record to enable early screening.

Israel’s Restart (see previously) has shifted its focus from rehabilitating IDF veterans, to supporting soldiers wounded in the current war. Its scanners and 3D printers at hospitals instantly make devices to help restore mobility. Restart’s volunteers are mostly wounded veterans themselves.

A CBS program that publicized the life-changing impact of the exoskeleton from Israel’s ReWalk (see previously) that enables wheelchair-bound US veterans to walk. CBS didn’t mention that the product was Israeli or even its name.

Israel’s Theranica (see previously) has reported successful long-term use of its Nerivio Remote Electrical Neuromodulation (REN) device for 409 migraine sufferers in the US. It consistently gave pain relief, functional disability relief and freedom.

Israel’s Magenta Medical (see previously) reported positive results in a 15-patient trial of its Elevate System. The percutaneous Left Ventricular Assist Device (pLVAD) supports circulation in high-risk percutaneous coronary interventions (HR-PCI).

Israel’s Can-Fite (see previously) is developing small molecule medicines that address oncology and inflammatory diseases. It has partnered with Collaborations Pharma to use AI and Machine Learning techniques that significantly reduce development time and costs.